

## Value of Ambulatory Care Measures

**■ eAppendix Table A. List of Metrics and Endorsement Status**

Measure	Clinical Domain	NQF/AQA/NCQA Endorse
Blood pressure < 140/90 mm Hg	HTN	Yes
Systolic blood pressure < 140 mm Hg	HTN	Yes
Diastolic blood pressure < 90 mm Hg	HTN	Yes
Blood pressure < 140/90 mm Hg (DM)	DM	Yes
A1C > 9%	DM	Yes
A1C < 7%	DM	Yes
LDL-C < 100 mg/dL (DM)	DM	Yes
LDL-C < 130 mg/dL (DM)	DM	Yes
LDL-C < 100 mg/dL after discharge for AMI, CABG, or PCI	CAD	Yes
LDL-C < 130 mg/dL after discharge for AMI, CABG, or PCI	CAD	Yes
LDL-C < 100 mg/dL with any CAD	CAD	Yes
LDL-C < 130 mg/dL with any CAD	CAD	Yes
Weight reduction (HTN)	HTN	Yes
BB use in HF	HF	Yes
ACE inhibitor/ARB use in LVSD	HF	Yes
BB post-MI with prescription 7 days after discharge	CAD	Yes
BB post-MI with prescription 6 months after discharge	CAD	Yes
Antiplatelet therapy in CAD—aspirin only	CAD	Yes
ACE inhibitor/ARB in CAD with LVSD	CAD	Yes
Back pain—bed rest > 4 days	ACC	Yes
Upper respiratory infection—no use of antibiotics	ACC	Yes
UTI—antibiotic use for < 7 days	ACC	
Use of warfarin in HF and atrial fibrillation	HF	Yes
Retinal eye screening (DM)	DM	Yes
Microalbuminuria screening past year (DM)	DM	Yes
Microalbuminuria screening (DM)	DM	Yes
Use of appropriate medications in AST	AST	Yes
Pharmacologic therapy (AST)	AST	Yes
Effective acute-phase treatment in DEP	DEP	Yes
Decongestant used < 4 days in nasal congestion	ACC	
Effective continuation-phase treatment (DEP)	DEP	Yes
Assessment of volume overload (HF)	HF	Yes
History taking for “red flags” in ALBP	ALBP	Yes
History taking for cauda equina symptoms in ALBP	ALBP	
ALBP—physical exam	ALBP	Yes
Optimal practitioner contacts (DEP)	DEP	Yes
Foot examination (DM)	DM	Yes
Measurement of serum creatinine (HTN)	HTN	
Avoiding contraindicated medications (ALBP)	ALBP	Yes

*(Continued)*

■ **eAppendix Table A.** List of Metrics and Endorsement Status

Measure	Clinical Domain	NQF/AQA/NCQA Endorse
Avoiding contraindicated physical treatments (ALBP)	ALBP	Yes
Classification of asthma	AST	
Lung function testing (AST)	AST	
Influenza vaccination for AST	AST	
Lipid profile (CAD)	CAD	Yes
LDL-C drug therapy (CAD)	CAD	Yes
Evaluation of activity level and anginal symptoms (CAD)	CAD	Yes
Annual A1C (DM)	DM	Yes
Lipid profile (DM)	DM	Yes
Assessment of left ventricular function (HF)	HF	Yes
Weight measurement within last 6 months (HF)	HF	Yes
Weight measurement (HF)	HF	Yes
Activity level documentation (HF)	HF	Yes
Plan of care (HTN)	HTN	Yes
Measurement of serum potassium (HTN)	HTN	Yes
Electrocardiogram (HTN)	HTN	
NSAID and analgesic use in OA	OA	Yes
Assessment of function and pain (OA)	OA	Yes
History taking for knee pain	Pain	
UTI—documentation of flank pain, fever, and dysuria	ACC	
UTI—documentation of vaginal discharge	ACC	
UTI—Bactrim as first-line therapy	ACC	
Sodium restriction (HTN)	HTN	Yes

NQF indicates National Quality Forum; AQA, Ambulatory care Quality Alliance; NCQA, National Committee for Quality Assurance; HTN, hypertension; DM, diabetes mellitus; A1C, glycosylated hemoglobin; LDL-C, low-density lipoprotein cholesterol; AMI, acute myocardial infarction; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; CAD, coronary artery disease; BB,  $\beta$ -blocker; HF, heart failure; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; ACC, acute-care condition; UTI, urinary tract infection; AST, asthma; DEP, depression; ALBP, acute lower back pain; NSAID, nonsteroidal anti-inflammatory drug; OA, osteoarthritis.

## ■ eAppendix Table B. Article Review

**Acute-care Conditions:**

- Adelman J, et al.** Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. *Headache*. 2002;42:978-983.
- Agency for Healthcare Research and Quality.** Estimated accuracy of medical history in diagnosis of spine disease causing low back problems [Table 1]. Acute Lower Back Problems in Adults. Clinical Practice Guideline 14. AHCPR publication 95-0642. December 1994. <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6.table.26921>. Accessed March 6, 2008.
- Arroll B, et al.** Corticosteroid injections for painful shoulder: a meta-analysis. *British Journal of General Practice*. 2005;224-228.
- Arroll B, et al.** Antibiotics for the common cold and acute purulent rhinitis. *Cochrane Database of Systematic Reviews*. 2006.
- Ashina S, et al.** Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. *Pain*. 2004;108:114.
- Bartlett J, et al.** Community-acquired pneumonia. *New England Journal of Medicine*. 1995;333(24):1618-1624.
- Berger R.** The urine dipstick test useful to rule out infections. A meta-analysis of the accuracy. *American Urological Association*. 2005;174(3):941-942.
- Bongers P.** The cost of shoulder pain at work. *BMJ*. 2001;322:64-65.
- Borge J, et al.** Prognostic values of physical examination findings in patients with chronic low back pain treated conservatively: a systematic literature review. *J Manipulative Physiol Ther*. 2001;24(4):292-295.
- Brox J.** Shoulder pain. *Best Practice & Research Clinical Rheumatology*. 2003;17(1):33-56.
- Buchbinder R, et al.** Corticosteroid injections for shoulder pain. *Cochrane Database of Systematic Reviews*. 2003.
- Calmbach W, et al.** Evaluation of patients presenting with knee pain: part I. History, physical examination, radiographs, and laboratory tests. *American Academy of Family Physician*. 2003;68(5):907-912.
- Carette S, et al.** Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. *Arthritis & Rheumatism*. 2003;48(3):829-838.
- Chronicle E, et al.** Anticonvulsant drugs for migraine prophylaxis. *Cochrane Database of Systematic Reviews*. 2004.
- Colombo B, et al.** Therapy of primary headaches: the role of antidepressants. *Neurol Sci*. 2004;25:171-175.
- Devillé W, et al.** The urine dipstick test useful to rule out infections: a meta-analysis of the accuracy. *BMC Urology*. 2004;4:1-14.
- Diamant A.** Orthopedic conditions. *RAND Clinical Practice Guideline*. 1994.
- Dinnes J, et al.** The effectiveness of diagnostic tests for the assessment of shoulder pain due to soft tissue disorders: a systematic review. *Health Technology Assessment*. 2003;7(29):1-178.
- Ebell M, et al.** Does this patient have strep throat? *JAMA*. 2000;284(22):2912-2918.
- Fenwick EAL, et al.** Management of urinary tract infection in general practice: a cost-effectiveness analysis. *British Journal of General Practice*. 2000;50:635-639.
- Fihn S.** Acute uncomplicated urinary tract infection in women. *New England Journal of Medicine*. 2003;349:259-266.
- Frishberg B, et al.** Evidence-based guidelines in the primary care setting: neuroimaging in patients with nonacute headache. *American Academy of Neurology*.
- Goldberg L.** The cost of migraine and its treatment. *American Journal of Managed Care*. 2005;11(2):62-67.
- Green S, et al.** Interventions for shoulder pain. *Cochrane Database of Systematic Reviews*. 2000.
- Gupta K, et al.** Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. *Annals Internal Medicine*. 2001;135:41-50.
- Hagen KB, et al.** Bed rest for acute low-back pain and sciatica. *Cochrane Database of Systematic Reviews*. 2005.
- Hay TM, et al.** A pragmatic randomised controlled trial of local corticosteroid injection and physiotherapy for the treatment of new episodes of unilateral shoulder pain in primary care. *Ann Rheum Dis*. 2003;62:394-399.
- James M, et al.** A cost consequences analysis of local corticosteroid injection and physiotherapy for the treatment of new episodes of unilateral shoulder pain in primary care. *Rheumatology*. 2005;44:1447-1451.
- Joines J, et al.** Finding cancer in primary care outpatients with lower back pain. *J Gen Intern Med*. 2001;16:14-23.
- Katchman E, et al.** Three-day vs longer duration of antibiotic treatment for cystitis in women: systematic review and meta-analysis. *American Journal of Medicine*. 2005;118:1196-1207.
- Kerr E, et al.** Upper respiratory infections. *RAND Clinical Practice Guideline*. 1994.
- Kerr E, et al.** Urinary tract infections. *RAND Clinical Practice Guideline*. 1994.
- Knutson D, et al.** Diagnosis and management of acute bronchitis. *American Family Physician*. 2002;65(10):2039-2046.
- Koester M, et al.** Shoulder impingement syndrome. *American Journal of Medicine*. 2005;118:452-455.
- Lapuerta P, et al.** Headache. *RAND Clinical Practice Guideline*. 1994.
- Leardina G, et al.** Direct and indirect costs of osteoarthritis of the knee. *Clin Exp Rheumatol*. 2004;22(6):699-706.
- Lofland J, et al.** Oral serotonin receptor agonists. A review of their cost effectiveness in migraine. *Pharmacoeconomics*. 2005;23(3):259-274.
- Ludewig PM, et al.** Effects of a home exercise programme on shoulder pain and functional status in construction workers. *Occup Environ Med*. 2003;60:841-849.
- Maher CG.** Effective physical treatment for chronic low back pain. *Orthopedic Clinics of North America*. 2004;35:57-64.
- Malmivaara A, et al.** The treatment of acute low back pain – bed rest, exercises, or ordinary activity? *New England Journal of Medicine*. 1995;332(6):351-355.
- Matchar D, et al.** Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. *American Academy of Neurology*.
- McGlynn E, et al.** Low back pain (acute). *RAND Clinical Practice Guideline*. 1994.
- McGuirk B, et al.** Safety, efficacy, and cost effectiveness of evidence-based guidelines for the management of acute low back pain in primary care. *Spine*. 2001;26(23):2615-2633.
- Milo G, et al.** Duration of antibacterial treatment for uncomplicated urinary tract infection in women. *Cochrane Database of Systematic Reviews*. 2005.
- Moja PL, et al.** Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. *Cochrane Database of Systematic Reviews*. 2005.
- Pai S, et al.** Low back pain: an economic assessment in the United States. *Orthopedic Clinics of North America*. 2004;35:1-5.
- Ramadan N, et al.** Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. *American Academy of Neurology*.
- Roer N, et al.** What is the most cost-effective treatment for patients with low back pain? A systematic review. *Best Practice & Research Clinical Rheumatology*. 2005;19(4):671-684.
- Silberstein S, et al.** Migraine preventive medication reduces resource utilization. *Headache*. 2003;43:171-178.

(Continued)

■ eAppendix Table B. Article Review (Continued)

**Solomon D, et al.** Can history and physical examination be used as markers of quality?: An analysis of the initial visit note in musculoskeletal care original articles. *Medical Care*. 2000;38(4):383-391.

**Streder L, et al.** Interexaminer reliability in physical examination of patients with low back pain. *Spine*. 1997;22(7):814-820.

**Taverner D, et al.** Nasal decongestants for the common cold. *Cochrane Database of Systematic Reviews*. 2006.

**Van Dillen L, et al.** Reliability of physical examination items used for classification of patients with low back pain. *Phys Ther*. 1998;78(9):979-988.

**Waddell G, et al.** Normality and reliability in the clinical assessment of backache. *BMJ*. 1982;284(6328):1519-1523.

**Wald ER, et al.** A streptococcal score card revisited. *Pediatr Emerg Care*. 1998;14(2):109-111.

**Weiner D, et al.** Chronic low back pain in older adults: prevalence, reliability, and validity of physical examination findings. *J Am Geriatr Soc*. 2006;54(1):11-20.

**Woolley SL, et al.** Sore throat in adults—does the introduction of a clinical scoring system improve the management of these patients in a secondary care setting. *J Laryngol Otol*. 2005;119(7):550-555.

**Asthma Care:**

Influenza and pneumococcal vaccination coverage among persons aged 18-64 years with diabetes or asthma—United States, 2003. *MMWR*. 2004;53:1007-1012.

**Abadoglu O, et al.** Influenza vaccination in patients with asthma: effect on the frequency of upper respiratory tract infections and exacerbations. *Journal of Asthma*. 2004;41(3):279-283.

**Adams NP, et al.** Fluticasone versus placebo for chronic asthma in adults and children. *Cochrane Database of Systematic Reviews*. 2006.

**Bueving H.** Is influenza vaccination in asthma helpful? *Curr Opin Allergy Clin Immunol*. 2005;5(1):65-70.

**Cates CJ, et al.** Vaccines for preventing influenza in people with asthma. *Cochrane Database of Systematic Reviews*. 2006.

**Celli B.** The importance of spirometry in COPD and asthma effect on approach to management. *Chest*. 2000;117:15-19.

**Chroinin N.** Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. *Cochrane Database of Systematic Reviews*. 2006.

**Hak E, et al.** Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions. *Arch Intern Med*. 2005;165:274-280.

**Harper S, et al.** Prevention and control of influenza. *Morbidity and Mortality Weekly Report*. 2005;54:1-44.

**Heyneman C, et al.** Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. *The Annals of Pharmacotherapy*. 2002;36:1944-1949.

**National Quality Forum.** Standardizing Ambulatory Care Performance Measures Project: Asthma/Respiratory Illness. 2004.

**Murphy S, et al.** Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health; 1997.

**O'Byrne P, et al.** Pocket Guide for Asthma Management and Prevention. Global Strategy for Asthma Management and Prevention; 1995.

**Tata L, et al.** Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease. *Thorax*. 2003;58:835-839.

**Coronary Artery Disease Care:**

**Antithrombotic Trialists' Collaboration.** Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002; 324:71-86.

**Butler J, et al.** Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. *Journal of the American College of Cardiology*. 2004;43(11): 2036-2043.

**Caro J, et al.** Allocating funds for cardiovascular disease prevention in light of the NCEP ATP III Guidelines. *Am J Manag Care*. 2003;9: 477-489.

**Cholesterol Treatment Trialists' (CTT) Collaborators.** Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267-1278.

**Dickstein K, et al.** Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL Randomised Trial. *Lancet*. 2002;360:752-760.

**Everly M, et al.** Blocker underuse in secondary prevention of myocardial infarction. *Ann Pharmacother*. 2004;38:286-293.

**Fletcher M, et al.** Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. *Lancet*. 2000;355:1575-1581.

**Fletcher B, et al.** Managing abnormal blood lipids a collaborative approach. *Circulation*. 2005;112:3184-3209.

**Freemantle N, et al.** Blockade after myocardial infarction: systematic review and meta regression analysis. *BMJ*. 1999;318:1730-1737.

**Gaspoz J, et al.** Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. *New England Journal of Medicine*. 2003;348:560.

**Gottlieb S, et al.** Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. *New England Journal of Medicine*. 1998;339(8):489-498.

**Grimshaw J, et al.** Changing provider behavior: an overview of systematic reviews of interventions. *Medical Care*. 2001;39(8):II-2-II-45.

**Grundy S, et al.** Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *Circulation*. 2004;110:227-239.

**Hennekens C.** Update on aspirin in the treatment and prevention of cardiovascular disease. *Am J Manag Care*. 2002;8:S691-S700.

**Jones L, et al.** Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. *Health Technology Assessment*. 2004;8(38): 3-221.

**Knatterud G, et al.** Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. *Circulation*. 2000;102:157-165.

**Lee V, et al.** Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. *Ann Intern Med*. 2004;141:693-704.

**Lewis B, et al.** Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study. *Am Heart J*. 2005;150: 1177-1184.

**Mahoney E, et al.** Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. *Am Heart J*. 2006;151:219-227.

**McDonald M, et al.** Angiotensin receptor blockers and risk of myocardial infarction: systematic review. *BMJ*. 2005;331(7521): 873-879.

**National Quality Forum.** Standardizing ambulatory care. *Performance Measures Project: Coronary Artery Disease*. 2004.

**Pharoah P, et al.** Cost effectiveness of lowering cholesterol concentration with statin disease: life table method applied to health authority population. *BMJ*. 1996;312:1443-1448.

(Continued)

■ **eAppendix Table B. Article Review (Continued)**

- Phillips K, et al.** Health and economical benefits of increased blocker use following myocardial infarction. *JAMA*. 2000;284:2748-2754.
- Pickin D, et al.** Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. *Heart*. 1999;82:325-332.
- Probstfield J.** How cost-effective are new preventive strategies for cardiovascular disease? *Am J Cardiol*. 2003;91:22G-27G.
- Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S). *Lancet*. 1994;344:1383-1389.
- Ross S, et al.** Clinical outcomes in statin treatment trials. *Arch Intern Med*. 1999;159:1793-1802.
- Sacks F, et al.** The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. *New England Journal of Medicine*. 1996;355(14):1001-1009.
- Schädlich P, et al.** Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of statutory health insurance. *Pharmacoeconomics*. 1998;14(6):653-659.
- Schwartz G, et al.** Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomized controlled trial. *JAMA*. 2001;285(13):1711-1719.
- Scleinitz MD, et al.** A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. *Ann Intern Med*. 2005;142:251-259.
- Shekelle PD, et al.** Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. *J Am Coll Cardiol*. 2003; 41:1529-1538.
- The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group.** Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *New England Journal of Medicine*. 2006;339(19):1349-1357.
- The Post Coronary Artery Bypass Graft Trial Investigators.** The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. *New England Journal of Medicine*. 1997;336(3):153-162.
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel.** Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Institutes of Health; 2002.
- Depression Care:**
- Croghan T, et al.** Cost effectiveness of antidepressant medications. *The Journal of Mental Health Policy and Economics*. 1998;1:109-117.
- Davidson J, et al.** The underrecognition and undertreatment of depression: what is the breadth and depth of the problem? *J Clin Psychiatry*. 1999;60(7):4-9.
- Geddes J, et al.** Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. *Lancet*. 2003; 361:653-661.
- Greenberg P, et al.** The economic burden of depression in the United States: How did it change between 1990 and 2000? *J Clin Psychiatry*. 2003;64:1465-1474.
- Katon W, et al.** Cost-effectiveness of improving primary care treatment of late-life depression. *Arch Gen Psychiatry*. 2005;62:1313-1320.
- Keller M, et al.** Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. *Biological Psychiatry*. 1998;44:348-360.
- Kessler R, et al.** The epidemiology of major depressive disorder results from the National Comorbidity Survey Replication (NCS-R). *JAMA*. 2003;289(23):3095-3105.
- Melfi C, et al.** The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. *Arch Gen Psychiatry*. 1998;55:1128-1132.
- National Quality Forum.** Standardizing Ambulatory Care Performance Measures Project: Behavioral Health/Depression. 2004.
- Olfson M, et al.** Continuity of antidepressant treatment for adults with depression in the United States. *Am J Psychiatry*. 2006; 163:101-108.
- Paykel ES.** Continuation and maintenance therapy in depression. *British Medical Bulletin*. 2001;57:145-159.
- Practice Guideline for the Treatment of Patients With Major Depressive Disorder.** 2nd ed. Rosslyn, VA: American Psychiatric Association; 2000.
- Schulberg H, et al.** Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. *Arch Gen Psychiatry*. 1998;55:1121-1127.
- Stewart W, et al.** Cost of lost productive work time among US workers with depression. *American Medical Association*. 2003;289(23):3135-3144.
- Wang P, et al.** Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62:603-613.
- Diabetes Care:**
- Adler A, et al.** Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ*. 2000;321:412-419.
- American Diabetes Association.** Standards of medical care in diabetes. *Diabetes Care*. 2004;27(1):S15-S35.
- Boulware LE, et al.** Screening for proteinuria in US adults. *JAMA*. 2003;290:3101-3114.
- Brandle M, et al.** Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes. *Diabetes Care*. 2003;26:1796-1801.
- Cholesterol Treatment Trialists' (CTT) Collaborators.** Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366:1267-1278.
- Ciulla T, et al.** Diabetic retinopathy and diabetic macular edema. *Diabetes Care*. 2003;26:2653-2664.
- Clarke P, et al.** Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). *Diabetologia*. 2005;48:868-877.
- Corvol J, et al.** Differential effects of lipid-lowering therapies on stroke prevention. *Arch Intern Med*. 2003;163:669-676.
- Gæde P, et al.** Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *New England Journal of Medicine*. 2003;348(5):383-393.
- Gerstein C.** Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. *Diabetes Metabolism Research and Reviews*. 2002;18:S82-S85.
- Gerstein H, et al.** Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA*. 2001;286:421-426.
- Grover S, et al.** Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? *Circulation*. 2000;102:722-727.
- Heart Outcomes Prevention Evaluation (HOPE) Study Investigators.** Effects of ramipril on cardiovascular and microvascu-  
(Continued)

■ **eAppendix Table B. Article Review (Continued)**

lar outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. *Lancet*. 2000;355:253-259.

**Ismail N, et al.** Renal disease and hypertension in non-insulin-dependent diabetes mellitus. *Kidney International*. 1999;55:1-28.

**Jawa A, et al.** Diabetic nephropathy and retinopathy. *Medical Clinics of North America*. 2004;88:1001-1036.

**Joyce A, et al.** End-stage renal disease-associated managed care costs among patients with and without diabetes. *Diabetes Care*. 2004;27:2829-2835.

**Liu J, et al.** Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. *Diabetes Care*. 2005;28:1916-1921.

**Minshall M, et al.** Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States. *Clinical Therapeutics*. 2005;27(6):940-950.

**Ortegon M, et al.** Cost-effectiveness of prevention treatment of the diabetic foot. *Diabetes Care*. 2004;27:901-907.

**Ragnarson Tennvall G, et al.** Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. *Diabetologia*. 2001;44:2207-2087.

**Rippin J, et al.** Cost-effective strategies in the prevention of diabetic nephropathy. *Pharmacoeconomics*. 2004;22(1):9-28.

**Selvin E, et al.** Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med*. 2004;141:421-431.

**Singer D, et al.** Screening for diabetic retinopathy. *Ann Intern Med*. 1992;116(8):660-671.

**Singh N, et al.** Preventing foot ulcers in patients with diabetes. *JAMA*. 2005;293(2):217-228.

**Spoelstra-de Man A, et al.** Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. *Diabetes Care*. 2001;24:2097-2101.

**Stratton I, et al.** Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*. 2000;321:405-412.

**The CDC Diabetes Cost-effectiveness Group.** Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type II diabetes. *JAMA*. 2002;287:2542-2551.

**Tuttle K, et al.** Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. *Am J Kidney Dis*. 1999;34(5):918-925.

**UK Prospective Diabetes Study Group.** Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ*. 1998;317:713-720.

**UK Prospective Diabetes Study (UKPDS) Group.** Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837-853.

**UK Prospective Diabetes Study Group.** Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703-713.

**Vijan S, et al.** Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. *JAMA*. 2000;283(7):889-896.

**Vijan S, et al.** Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. *Ann Intern Med*. 1997;127:788-795.

**Vijan S, et al.** Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. *Ann Intern Med*. 2004;140:650-658.

**Vijan S, et al.** Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. *Ann Intern Med*. 2003;138:593-602.

**Heart Failure Care:**

**Bridgett RG.** Can the clinical examination diagnose left-sided heart failure in adults? *JAMA*. 1997;277(21):1712-1719.

**Brophy J, et al.** Beta blockers in congestive heart failure—a Bayesian meta-analysis. *Ann Intern Med*. 2001;134:550-560.

**Buxton A.** Risk stratification for sudden death: do we need anything more than ejection fraction? *Card Electrophysiol Rev*. 2003;7(4):434-437.

**Cowper PA, et al.** Economic effects of beta-blocker therapy in patients with heart failure. *Am J Med*. 2004;116:104-111.

**Dickstein K, et al.** ELITE II and Val-HeFT are different trials: together what do they tell us? *Curr Control Trials Cardiovasc Med*. 2001;2:240-243.

**Dimopoulos K, et al.** Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). *International Journal of Cardiology*. 2004;93:105-111.

**Drazner M.** Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. *New England Journal of Medicine*. 2001;345:574-581.

**Dulin B, et al.** Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. *American Journal of Cardiology*. 2005;95:896-898.

**Fogel M.** Use of ejection fraction (or lack thereof), morbidity/mortality and heart failure drug trials: a review. *International Journal of Cardiology*. 2002;84:119-132.

**Gage B, et al.** Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. *JAMA*. 1996;275(12):909.

**Gage B, et al.** Validation of clinical classification schemes for predicting stroke—results from the National Registry of Atrial Fibrillation. *JAMA*. 2001;285:2864-2870.

**Garber A, et al.** Cost-effectiveness of alternative test strategies for the diagnosis of coronary artery disease. *Ann Intern Med*. 1999;130:719-728.

**Glick H, et al.** Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies Of Left Ventricular Dysfunction (SOLVD) treatment trial. *J Card Fail*. 1995(5):371-380.

**Goldberg L.** Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: the Weight Monitoring In Heart Failure (WHARF) trial. *Am Heart J*. 2003;146:705-712.

**Gregory D, et al.** Economic impact of beta blockade in heart failure. *Am J Med*. 2001;110(7A):74S-80S.

**Haas S, et al.** Are blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. *American Heart Journal*. 2003;146(5):848-853.

**Hart A.** Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database of Systematic Reviews*. 2005;3:CD001927.

**Hart R, et al.** Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 1999;131:492-501.

**Hunt SA, et al.** ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. *ACC/AHA Practice Guidelines*. 2005.

**Khot U, et al.** Prognostic importance of physical examination for heart failure in non-ST-elevation acute coronary syndromes: the enduring value of Killip classification. *JAMA*. 2003;290(16):2174-2181.

**Konstam MA, et al.** Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the Losartan Heart Failure Survival Study (ELITE II). *American Heart Journal*. 2005;150(1):123-131.

(Continued)

## ■ eAppendix Table B. Article Review (Continued)

- Krum H, et al.** Pharmacoeconomics of beta-blockers: effective and cost-effective therapy in chronic heart failure. *European Journal of Heart Failure*. 2001;3:399-402.
- Lewin J, et al.** Clinical deterioration in established heart failure: what is the value of BNP and weight gain in aiding diagnosis? *Ann Intern Med*. 1999;130:719-728.
- Levy AR, et al.** Cost-effectiveness of  $\beta$ -blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. *Am Heart J*. 2001;142:537-543.
- McMurray J.** Major blocker mortality trials in chronic heart failure: a critical review. *Heart*. 1999;82:IV14-IV22.
- National Quality Forum.** Standardizing Ambulatory Care Performance Measures Project: Heart Failure. 2004.
- New directions for cardiovascular medicine. *Lancet*. 2003;362:754-755.
- Pullicino P, et al.** Warfarin versus Aspirin in Patients With Reduced Cardiac Ejection Fraction (WARCEF): rationale, objectives, and design. *J Card Fail*. 2006;12(1):39-46.
- Rame J, et al.** The prognostic value of the physical examination in patients with chronic heart failure. *Congest Heart Fail*. 2003;9(3):170-175,178.
- Reynolds M, et al.** Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. *Chest*. 2004;126:1938-1945.
- Scott W, et al.** Heart failure. A decision analytic analysis of New Zealand data using the published results of the SOLVD treatment trial. Studies of left ventricular dysfunction. *Pharmacoeconomics*. 1996;9(2):156-167.
- Shibata MC, et al.** Economic implications of treatment guidelines for congestive heart failure. *Can J Cardiol*. 2005;21(14):1301-1306.
- Skrepnek G, et al.** Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. *The Annals of Pharmacotherapy*. 2005;(39):1785-1791.
- Smith D, et al.** Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. *Clinical Therapeutics*. 2005;27:951-959.
- Swedberg K, et al.** Long-term survival in severe heart failure in patients treated with enalapril. *European Heart Journal*. 1999;20:136-139.
- The SOLVD Investigators.** Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *New England Journal of Medicine*. 1991;325(5):293-302.
- Thomas J.** Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. *American Journal of Medicine*. 2002;112:437-445.
- Vera-Llonch M, et al.** Cost-effectiveness results from the US Carvedilol Heart Failure Trials program. *Ann Pharmacother*. 2001;35:846-851.
- Hypertension Care:**
- Adler A, et al.** Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. *BMJ*. 2000;321:412-419.
- Alderman M, et al.** Dietary sodium and cardiovascular health in hypertensive patients: the case against universal sodium restriction. *Journal of the American Society of Nephrology*. 2004;15:S47-S50.
- Ambrosioni E.** Pharmacoeconomics of hypertension management: the place of combination therapy. *Pharmacoeconomics*. 2001;19(4):337-347.
- Ashley E, et al.** An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. *Progress in Cardiovascular Diseases*. 2001;4(1):55-67.
- Cappuccio FP, et al.** Does potassium supplementation lower blood pressure? A meta-analysis of published trials. *J Hypertens*. 1991;9(5):465-473.
- Clinical Performance Measures: Hypertension.** American Medical Association. 2003.
- Douketis J, et al.** The management of hypertension in the overweight and obese patient. Is weight reduction sufficient? *Drugs*. 2004;64(8):795-803.
- Franklin S, et al.** Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. *Circulation*. 2001;103:1245-1249.
- Galasko G, et al.** What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination? *European Heart Journal*. 2006;27:193-200.
- Ganguly A, et al.** Primary aldosteronism. *New England Journal of Medicine*. 1998;339(25):1829-1834.
- Gaziano T, et al.** Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. *Circulation*. 2005;112:3569-3576.
- Gennari F, et al.** Hypokalemia. *New England Journal of Medicine*. 1998;339(7):451-458.
- Graudal N, et al.** Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride. A meta-analysis. *JAMA*. 1998;279(17):1383-1391.
- Hedberg P, et al.** Electrocardiogram and B-type natriuretic peptide as screening tools for left ventricular systolic dysfunction in a population-based sample of 75-year-old men and women. *American Heart Journal*. 2004;148(3):525-529.
- Khunti K, et al.** Accuracy of a 12-lead electrocardiogram in screening patients with suspected heart failure for open access echocardiography: a systematic review and meta-analysis. *European Journal of Heart Failure*. 2004;6:571-576.
- Lapuerta P, et al.** Assessment of the association between blood pressure control and health care resource use. *Clinical Therapeutics*. 2001;23(10):1773-1782.
- McTigue K, et al.** Screening and interventions for obesity in adults: summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2003;139(11):933-966.
- Midgley JP, et al.** Effect of reduced dietary sodium on blood pressure: a meta-analysis of randomized controlled trials. *JAMA*. 1996;275(20):1590-1597.
- Montgomery A, et al.** The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. *Journal of Hypertension*. 2003;21:1753-1759.
- Mullins C, et al.** Comparing cost-effectiveness analyses of anti-hypertensive drug therapy for decision making: mission impossible? *Value in Health*. 2002;5(4):359-371.
- Mulrow CD, et al.** Dieting to reduce body weight for controlling hypertension in adults. *Ann Intern Med*. 2003;139:933-949.
- Murray C, et al.** Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet*. 2003;361:717-725.
- National Quality Forum.** Standardizing Ambulatory Care Performance Measures Project. *Hypertension*. 2004.
- Neter J, et al.** Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. *Hypertension*. 2003;42:878-884.
- Oster G, et al.** Lifetime health and economic benefits of weight loss among obese persons. *American Journal of Public Health*. 1999;89(10):1536-1542.
- Ryan M, et al.** The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. *American Journal of Cardiology*. 1995;76:689-694.
- Schillaci G, et al.** High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. *Arch Intern Med*. 2001;161:886-891.

(Continued)

■ eAppendix Table B. Article Review (Continued)

**Shepard DS, et al.** Cost effectiveness of intensive treatment of hypertension. *Am J Manag Care.* 1998;4(12S):S765-S769.

**Shigematsu Y, et al.** Serum creatinine level underestimates hypertensive renal involvement in elderly patients with essential hypertension. *Hypertens Res.* 1999;22(4):297-301.

**Shiner T, et al.** The financial cost of optimising blood pressure control. *Journal of Human Hypertension.* 2005;19:83-84.

**Shulman NB, et al. The Hypertension Detection and Follow-Up Program Cooperative Group.** Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-Up Program. *Hypertension.* 1989;13(5S):180-193.

**Staessen J, et al.** Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. *JAMA.* 1999;282(6):539-546.

The Seventh Report of The Joint National Committee on Prevention, Detection, Evaluation, And Treatment of High Blood Pressure. Bethesda, MD: National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute; September 2004:1-86. NIH publication 04-5230.

**Toto R, et al.** Evaluation of serum creatinine for estimating glomerular filtration rate in African Americans with hypertensive nephrosclerosis: results from the African-American Study of Kidney Disease and Hypertension (AASK) pilot study. *Journal of the American Society of Nephrology.* 1997;8:280-287.

US Preventive Services Task Force. *Screening for Obesity in Adults.* 2003.

**Viazi F, et al.** Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. *Journal of Hypertension.* 2004;22(5):907-913.

**Whelton PK, et al.** Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. *JAMA.* 1997;277(20):1624-1632.

**Whelton PK, et al.** Potassium in preventing and treating high blood pressure. *Semin Nephrol.* 1999;19(5):494-499.

**Osteoarthritis Care:**

American Academy of Orthopaedic Surgeons Department of Research and Scientific Affairs. Osteoarthritis of the Knee Care Flow Chart. 2003.

ICSI Health Care Guideline: Diagnosis and Treatment of Adult Degenerative Joint Disease (DJD) of the Knee. 8th ed. November 2004.

**Kamath C, et al.** The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. *Value in Health.* 2003;6(2):144-157.

**National Quality Forum.** Standardizing Ambulatory Care Performance Measures Project: Bone Disease. 2004.

Recommendations for the medical management of osteoarthritis of the hip and knee. *Arthritis & Rheumatism.* 2000;43(9):1905-1915.

**Spiegel B, et al.** The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. *Ann Intern Med.* 2003;138:795-806. ■